NCT02735707(1010. ClinicalTrials.gov. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). Bethesda: National Library of Medicine; 2016 [cited 2020 Oct 28]. [First posted Apr 13, 2016; Last update posted Oct 12, 2020]. Available from: https://ClinicalTrials.gov/show/NCT02735707 https://ClinicalTrials.gov/show/NCT02735...
)
|
IV |
Severe acute respiratory illness and severe community acquired pneumonia |
Corticosteroid versus antibiotics versus macrolide versus Influenza antiviral versus LPV/Rit versus HydChl versus IFN-β1a versus Anak versus Tmab versus Smab versus Vit C versus heparin versus simvastatin versus CP versus ST |
1 or 2 units within 48 hours |
>18 |
4/11/16 |
12/1/23 |
58 |
Recruitingz |
NCT04391101(1111. ClinicalTrials.gov. Convalescent plasma for patients with COVID-19: a pilot study. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 2, 2020; Last update posted Aug 17, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04332380 https://ClinicalTrials.gov/show/NCT04332...
)
|
III |
Severe patients treated in ICU |
CP associated with ST versus ST |
400-500mL |
>18 |
6/1/20 |
12/1/21 |
19.2 |
Not yet recruiting |
NCT04372979(1212. ClinicalTrials.gov. Efficacy of convalescent plasma therapy in the early care of COVID-19 patients (PLASCOSSA). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 4, 2020; Last update posted Oct 26, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04372979 https://ClinicalTrials.gov/show/NCT04372...
)
|
III |
Early care of hospitalized patients |
CP associated with ST versus SP associated with ST |
200-230mL |
18-80 |
5/1/20 |
5/1/21 |
37.3 |
Not yet recruiting |
NCT04418518(1313. ClinicalTrials.gov. A trial of CONvalescent plasma for hospitalized adults with acute COVID-19 respiratory illness (CONCOR-1). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted June 5, 2020; Last update posted July 7, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04418518 https://ClinicalTrials.gov/show/NCT04418...
)
|
III |
Early care for patients hospitalized |
CP associated with ST versus ST |
500mL of single-donor or 2 units of 250mL from 1-2 donations |
18-70 |
6/24/20 |
12/1/21 |
15.6 |
Recruiting |
NCT04355767(1414. ClinicalTrials.gov. Convalescent plasma in outpatients with COVID-19 (C3PO). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 21, 2020; Last update posted Sep 29, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04355767 https://ClinicalTrials.gov/show/NCT04355...
)
|
III |
Severe/critical hospitalized patients |
CP (antibodies titers ≥1:160) versus placebo |
CP: 1-unit versus placebo: saline with multivitamin |
>18 |
8/11/20 |
12/1/22 |
4.0 |
Not yet recruiting |
NCT04432103(1515. ClinicalTrials.gov. Treatment of severe and critical COVID-19 pneumonia with convalescent plasma. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted June 16, 2020; Last update posted June 17, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04432103 https://ClinicalTrials.gov/show/NCT04432...
)
|
III |
Severe/critical hospitalized patients |
CP from IgG (severe patients versus critical patients) associated with ST |
NR |
>19 |
6/19/20 |
9/30/20 |
84.5 |
Not yet recruiting |
NCT04348656(1616. ClinicalTrials.gov. CONvalescent plasma for hospitalized adults with COVID-19 respiratory illness (CONCOR-1). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 16, 2020; Last update posted Oct 20, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04348656 https://ClinicalTrials.gov/show/NCT04348...
)
|
III |
Early care for patients hospitalized |
CP versus ST |
500mL of single-donor or 2 units of 250mL from 1-2 donations |
>20 |
5/14/20 |
12/31/20 |
53.2 |
Recruiting |
NCT04425915(1717. ClinicalTrials.gov. Efficacy of convalescent plasma therapy in patients with COVID-19. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted June 11, 2020; Last update posted Sep 3, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04425915 https://ClinicalTrials.gov/show/NCT04425...
)
|
III |
Severe/critical hospitalized patients |
CP associated with ST versus ST |
2 doses of 250mL on consecutive day started by day 3 of symptom onset |
>21 |
6/14/20 |
5/30/21 |
26.3 |
Recruiting |
NCT04362176(1818. ClinicalTrials.gov. Passive immunity trial of the nation for COVID-19 (PassItOnII). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 24, 2020; Last update posted Aug 27, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04362176 https://ClinicalTrials.gov/show/NCT04362...
)
|
III |
Patients hospitalized or in ICU |
Pathogen reduced CP versus placebo |
CP: 500mL within 12 hours (day 0) versus placebo: 250mL of Lactate Ringers associated with multivitamins (day 1) |
>22 |
4/24/20 |
4/1/21 |
41.8 |
Recruiting |
NCT04381858(1919. ClinicalTrials.gov. Convalescent plasma vs human immunoglobulin to treat COVID-19 pneumonia. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 11, 2020; Last update posted May 12, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04381858 https://ClinicalTrials.gov/show/NCT04381...
)
|
III |
Severe respiratory failure with invasive mechanical ventilation |
CP (antibodies titers >1:164) versus HIg |
CP: 400mL (2 units) versus HIg: 0.3g/kg/day (5 doses) |
16-18 |
5/6/20 |
9/30/20 |
89.1 |
Recruiting |
NCT04361253(2020. ClinicalTrials.gov. Evaluation of SARS-CoV-2 (COVID-19) antibody-containing plasma therapy (ESCAPE). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 24, 2020; Last update posted May 18, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04361253 https://ClinicalTrials.gov/show/NCT04361...
)
|
III |
Patients hospitalized |
CP (high-titer) versus SP (FFP or FP 24) |
HT-CP: 2 doses of 250mL of single donor within 24 hours; FFP: 2 units of 200-275mL |
>1 |
04/30/20 |
12/1/21 |
23.6 |
Recruiting |
NCT04376034(2121. ClinicalTrials.gov. Convalescent plasma collection and treatment in pediatrics and adults. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 6, 2020; Last update posted May 6, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04376034 https://ClinicalTrials.gov/show/NCT04376...
)
|
III |
Mild, moderate and severe/critical severity |
CP associated with ST versus ST |
Adult: 200 to 250mL; children: 10mL/kg; 2 units severe patients or critical condition |
>30 days |
4/16/20 |
3/30/21 |
43.4 |
Recruiting |
NCT04483960(2222. ClinicalTrials.gov. Australasian COVID-19 trial (ASCOT) [Internet]. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted July 23, 2020; Last update posted July 23, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04483960 https://ClinicalTrials.gov/show/NCT04483...
)
|
III |
No severe patients |
LPV/Rit versus HydChl versus CP |
1 unit on day 1 and day 2 |
>18 |
7/21/20 |
6/12/22 |
8.0 |
Recruiting |
NCT0434528 9(2323. ClinicalTrials.gov. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 14, 2020; Last update posted July 31, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04345289 https://ClinicalTrials.gov/show/NCT04345...
)
|
III |
Mild, moderate and severe/critical hospitalized patients |
CP associated with ST (Smab versus baricitinib versus HydChl) versus ST associated with injective placebo |
CP: (twice 300mL) and single dose of 600mL; placebo: (twice 300mL) and single dose of 600mL IV saline oral placebo: three times/day (7 days) |
>18 |
5/1/20 |
6/15/21 |
33.2 |
Recruiting |
NCT04342182(2424. ClinicalTrials.gov. Convalescent plasma as therapy for Covid-19 severe SARS-CoV-2 disease (CONCOVID Study). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 10, 2020; Last update posted May 18, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04342182 https://ClinicalTrials.gov/show/NCT04342...
)
|
II-III |
Hospitalized patients |
CP associated with ST versus ST |
300mL (according to the Erasmus MC KIS protocol) |
>18 |
4/8/20 |
7/1/20 |
100 |
Recruiting |
NCT04388410(2525. ClinicalTrials.gov. Safety and efficacy of convalescent plasma transfusion for patients with COVID-19 (EPCOvid-1). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 14, 2020; Last update posted Aug 26, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04388410 https://ClinicalTrials.gov/show/NCT04388...
)
|
II-III |
Hospitalized patients with severe disease or at risk for severe disease. |
CP versus placebo |
CP: 2 units of 200mL within 24-72 hours); placebo: 200mL of saline |
>18 |
8/25/20 |
12/31/20 |
15.6 |
Not yet recruiting |
NCT04374526(2626. ClinicalTrials.gov. Early transfusIon of convalescent plasma in elderly COVID-19 patients. to prevent disease progression. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 5, 2020; Last update posted Oct 6, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04374526 https://ClinicalTrials.gov/show/NCT04374...
)
|
II-III |
Hospitalized patients |
CP associated with ST versus ST |
200mL/day for 3 days |
>65 |
5/27/20 |
6/30/21 |
27.6 |
Recruiting |
NCT04384588(2727. ClinicalTrials.gov. COVID19-convalescent plasma for treating patients with active symptomatic COVID 19 infection (FALP-COVID). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 12, 2020; Last update posted May 12, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04384588 https://ClinicalTrials.gov/show/NCT04384...
)
|
II-III |
Oncological and non-oncological patients with severe disease |
CP associated with ST versus ST |
1 or more units |
>15 |
4/7/20 |
4/6/21 |
44.0 |
Recruiting |
NCT04425837(2828. ClinicalTrials.gov. Effectiveness and safety of convalescent plasma in patients with high-risk COVID-19. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted June 11, 2020; Last update posted June 11, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04425837 https://ClinicalTrials.gov/show/NCT04425...
)
|
II-III |
Hospitalized patients at high risk of severe disease or in ICU |
CP (antibodies titers of ≥1:160) associated with ST versus ST |
2 doses of 200mL in a day |
>18 |
7/1/20 |
2/1/21 |
34.9 |
Not yet recruiting |
NCT04395170(2929. ClinicalTrials.gov. Convalescent plasma (PC) and human intravenous anti-COVID-19 immunoglobulin (IV anti COVID-19 IgG) in patients hospitalized for COVID-19. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28] [First posted May 20, 2020; Last update posted July 10, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04395170 https://ClinicalTrials.gov/show/NCT04395...
)
|
II-III |
Early care for patients hospitalized |
CP associated with ST versus anti-COVID-19 HIg versus ST |
CP: 200-250mL (day 1 and 3); 10% IgG solution: 50mL (patient ≥50kg); 1 mL/Kg (patient <50Kg), on days 1 and 3 |
>18 |
9/1/20 |
6/1/21 |
4.8 |
Not yet recruiting |
NCT04380935(3030. ClinicalTrials.gov. Effectiveness and safety of convalescent plasma therapy on COVID-19 patients with acute respiratory distress syndrome. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28] [First posted May 8, 2020; Last update posted Aug 18, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04380935 https://ClinicalTrials.gov/show/NCT04380...
)
|
II-III |
Hospitalized patients in ICU (using mechanical ventilation) |
CP associated with ST versus ST |
NR |
>18 |
5/18/20 |
10/31/20 |
71.7 |
Not yet recruiting |
NCT04332835(3131. ClinicalTrials.gov. Convalescent plasma for patients with COVID-19: a randomized, open label, parallel, controlled clinical study. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 3, 2020; Last update posted Sep 2, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04332835 https://ClinicalTrials.gov/show/NCT04332...
)
|
II-III |
Moderate and severe/critical severity |
CP associated with ST versus HyChl associated with ST |
250mL on days 1 and 2 |
18-60 |
8/8/20 |
10/31/20 |
44.0 |
Not yet recruiting |
NCT04385043(3232. ClinicalTrials.gov. Hyperimmune plasma in patients with COVID-19 severe infection. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 12, 2020; Last update posted May 12, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04385043 https://ClinicalTrials.gov/show/NCT04385...
)
|
II-III |
Severe/critical hospitalized patients |
CP associated with ST versus ST |
NR |
18-60 |
5/1/20 |
5/15/21 |
35.9 |
Recruiting |
NCT04381936(3333. ClinicalTrials.gov. Randomised evaluation of COVID-19 therapy. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 11, 2020; Last update posted Sep 29, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04381936 https://ClinicalTrials.gov/show/NCT04381...
)
|
II-III |
Hospitalized patients at high-risk of severe disease |
LPV/Ritversus corticosteroid versus HyChl versus Azi versus Tmab associated with ST versus CP associated with ST |
275mL±75mL on days 1 and 2 |
all |
3/19/20 |
12/1/31 |
4.2 |
Recruiting |